Skip to Content

Generic Nitrostat Availability

See also: Generic Nitro-Dur, Generic Nitrolingual Pumpspray, Generic NitroMist

Nitrostat is a brand name of nitroglycerin, approved by the FDA in the following formulation(s):

NITROSTAT (nitroglycerin - injectable;injection)

  • Manufacturer: PARKE DAVIS
    Approved Prior to Jan 1, 1982
    Strength(s): 0.8MG/ML
  • Manufacturer: PARKE DAVIS
    Approval date: December 23, 1983
    Strength(s): 5MG/ML

NITROSTAT (nitroglycerin - tablet;sublingual)

  • Manufacturer: PFIZER PHARMS
    Approval date: May 1, 2000
    Strength(s): 0.3MG, 0.4MG, 0.6MG [RLD]

Has a generic version of Nitrostat been approved?

An Authorized Generic version of Nitrostat has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

    Physicians Total Care, Inc.
    NDC Code: 548686045
    Greenstone LLC
    NDC Code: 597620489
    Greenstone LLC
    NDC Code: 597623304
    Greenstone LLC
    NDC Code: 597624921

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nitrostat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compressed nitroglycerin tablet and its method of manufacture
    Patent 6,500,456
    Issued: December 31, 2002
    Inventor(s): Roberto L.; Capella
    Assignee(s): Warner-Lambert Company
    The present invention is directed to a stable nitroglycerin containing pharmaceutical composition, preferably a tablet which is prepared by direct compression technology. The formulation closely replicates the properties of nitroglycerin molded sublingual tablets (e.g. adequate disintegration and sublingual absorption), while reducing the problems experienced with compressed tablets (e.g. friability and weight variations). The stable tablets are characterized by a decreased migration of nitroglycerin, decreased potency loss, excellent content uniformity when stored. The preferred combination of components are: nitroglycerin/lactose dilution, hydrous lactose, glyceril monostearate, fumed silica, pregelantinized starch and calcium stearate. The preferred process employs direct compression technology to yield composition showing adequate disintegration, bioavailability and improved stability.
    Patent expiration dates:
    • September 16, 2018


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.